SEC Form 4 · accession 0001209191-18-009385
ADURO BIOTECH, INC. · ADRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrea van Elsas
Officer — Chief Scientific Officer
Period of report
Feb 8, 2018
Accepted (ET)
Feb 12, 2018 · 8:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001435049
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.05 | Feb 8, 2018 | A | 135,650 | A | — | Feb 7, 2028 | Common Stock | 135,650 | 135,650 | D |
Explanation of responses
- F1The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 8, 2018.